Sunitinib

( DrugBank: Sunitinib / KEGG DRUG: Sunitinib )

2 diseases

ID	Disease name (Link within this page)	Number of trials
28	Systemic amyloidosis	1

ID	Disease name (Link within this page)	Number of trials
34	Neurofibromatosis	2

28. Systemic amyloidosis

Clinical trials : 267 / Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00890747 (ClinicalTrials.gov)	August 2009	29/4/2009	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	A Phase 1/Pharmacokinetic Study of Sunitinibin Patients With Cancer Who Also Have HIV and Are on HAA ...	Accelerated Phase Chronic Myelogenous Leukemia;Acute Myeloid Leukemia With Multilineage Dysplasia Fo ...	Drug: sunitinib malate;Other: pharmacological study;Other: laboratory biomarker analysis	National Cancer Institute (NCI)	NULL	Completed	18 Years	N/A	Both	42	Phase 1	United States

Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01402817 (ClinicalTrials.gov)	March 2012	25/7/2011	Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas	A Pilot Study of Sutent®/Sunitinib(SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor in Sub ...	Neurofibromatosis;NF1;Plexiform Neurofibromas	Drug: Sutent®/Sunitinib	Indiana University	United States Department of Defense;Pfizer	Terminated	3 Years	65 Years	All	19	Phase 2	United States
2	NCT00589784 (ClinicalTrials.gov)	October 2007	26/12/2007	Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma	Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma	CNS Cancer;Meningioma;Intracranial Hemangiopericytoma;Hemangioblastoma;Neurofibromatosis	Drug: Sunitinib	Memorial Sloan Kettering Cancer Center	Dana-Farber Cancer Institute;University of Virginia;University of Pittsburgh;Pfizer	Completed	18 Years	N/A	All	50	Phase 2	United States